Tradestie Institutional Equity Comparison Engine

ANRO vs MNOV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MNOV Overall Edge

MNOV Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Valuation, Growth & Margin, Options & Structure while ANRO counters with relative strength in Momentum & Technical. Fundamentally, ANRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MNOV at 8.5x Forward P/E and -1232.2% operating margin (+12.4% YoY). In options structure, ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MNOV
ANRO N/M vs MNOV 8.5x Fwd P/E
Growth & Margin Winner MNOV
Op Margin 0.0% vs -1232.2% ยท YoY +0.0% vs +12.4%
Momentum & Technical Winner ANRO
1Y +63.3% vs -8.4% ยท 52W Pos 52% vs 3%
Options & Structure Winner MNOV
BREAKDOWN (8th %ile IV) vs UNCLASSIFIED (50th %ile IV)
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.37
-4.3% 1D
Market Cap $1.1B
1M Return +14.28%
1Y Return +63.26%
Forward P/E N/M
Unified AI Score
45.8 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 65.0 Mom 50.0
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
1M Return -7.09%
1Y Return -8.39%
Forward P/E 8.5x
Unified AI Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ANRO +63.26% MNOV -8.39% Spread: +71.65 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ANRO TTM Op. Margin: 0.0% MNOV TTM Op. Margin: -1232.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs MNOV. Trailing 12-month operating profitability (ANRO 0.0% vs MNOV -1232.2%) and valuation multiples (ANRO N/M vs MNOV 8.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ANRO (3) vs MNOV (6)
Institutional Metric ANRO MNOV Criterion Row Winner
Market Capitalization Scale $1.1B $65.1M Larger Scale ANRO
Trailing P/E Ratio Valuation N/M 8.5x Lower Multiple MNOV
Forward P/E Ratio Valuation N/M 8.5x Lower Multiple MNOV
Revenue Growth (YoY) Growth +0.0% +12.4% Higher Growth MNOV
Operating Margin (TTM) Profitability 0.0% -1232.2% Higher Margin ANRO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -46.7% -24.8% Higher ROE MNOV
52-Week Range Position Momentum 52% ($13โ€“$37) 3% ($1โ€“$4) Stronger Trend ANRO
Beta / 30D Volatility Risk Regime 1.86ฮฒ ยท 91% Vol 0.59ฮฒ ยท 38% Vol Lower Realized Risk MNOV
Unified Institutional Score Composite Signal 45.8 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite MNOV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ANRO vs MNOV Buy Guide
ANRO BREAKDOWN
61d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ANRO nor MNOV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.